Comparing OrthoPediatrics (NASDAQ:KIDS) & Inspira Technologies Oxy B.H.N. (NASDAQ:IINN)

OrthoPediatrics (NASDAQ:KIDS) and Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, earnings and profitability.

Profitability

This table compares OrthoPediatrics and Inspira Technologies Oxy B.H.N.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-13.58%	-5.12%	-4.41%
Inspira Technologies Oxy B.H.N.	N/A	-158.18%	-108.21%

Valuation & Earnings

This table compares OrthoPediatrics and Inspira Technologies Oxy B.H.N.’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$148.73 million	4.69	-$20.97 million	($0.96)	-30.52
Inspira Technologies Oxy B.H.N.	N/A	N/A	-$11.29 million	N/A	N/A

Inspira Technologies Oxy B.H.N. has lower revenue, but higher earnings than OrthoPediatrics.

Analyst Recommendations

This is a summary of recent recommendations and price targets for OrthoPediatrics and Inspira Technologies Oxy B.H.N., as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	0	1	3	0	2.75
Inspira Technologies Oxy B.H.N.	0	0	0	0	N/A

OrthoPediatrics presently has a consensus price target of $45.50, indicating a potential upside of 55.29%. Given OrthoPediatrics’ higher probable upside, equities research analysts clearly believe OrthoPediatrics is more favorable than Inspira Technologies Oxy B.H.N..

Volatility & Risk

OrthoPediatrics has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Inspira Technologies Oxy B.H.N. has a beta of 2.19, indicating that its share price is 119% more volatile than the S&P 500.

Insider and Institutional Ownership

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 12.7% of Inspira Technologies Oxy B.H.N. shares are owned by institutional investors. 31.8% of OrthoPediatrics shares are owned by company insiders. Comparatively, 29.4% of Inspira Technologies Oxy B.H.N. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

OrthoPediatrics beats Inspira Technologies Oxy B.H.N. on 7 of the 10 factors compared between the two stocks.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.